Sam's Club Pharmacy vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Walmart-owned warehouse club pharmacy with 500+ locations; bulk purchasing enables discounted $4/$10 generics competing with Costco Pharmacy as part of Walmart's health services strategy.
About
Sam's Club Pharmacy is the pharmacy division operating within Sam's Club warehouse membership clubs, providing prescription filling, immunizations, health screenings, and specialty pharmacy services to Sam's Club members at competitive pricing leveraging Walmart's pharmaceutical purchasing scale. Part of Walmart Inc. (NYSE: WMT), Sam's Club Pharmacy operates more than 500 pharmacy locations inside Sam's Club warehouse clubs across the United States, offering members discounted prescription pricing as part of the Sam's Club membership value proposition.\n\nSam's Club Pharmacy's competitive advantage lies in Walmart's massive pharmaceutical purchasing power — the combined Walmart/Sam's Club pharmacy network is one of the largest in the US, enabling negotiated drug pricing that can undercut traditional retail pharmacies. Members access prescriptions at Sam's Club prices with convenient access during their warehouse shopping trips. The pharmacy offers $4/$10 generic prescription pricing for common medications, mail-order options, and immunization services.\n\nIn 2025, Sam's Club Pharmacy operates within Walmart's broader health strategy — Walmart Health (primary care clinics) and Walmart+ pharmacy benefits are being integrated to create a comprehensive health services ecosystem for Walmart and Sam's Club customers. The retail pharmacy market faces structural challenges from pharmacy benefit manager (PBM) reimbursement pressure that has forced independent and chain pharmacy closures. Sam's Club Pharmacy competes with Costco Pharmacy (similar warehouse model), CVS, Walgreens, and mail-order PBM pharmacies. The 2025 strategy focuses on expanding specialty pharmacy capabilities, integrating prescription benefits with Walmart+ membership, and growing immunization and preventive health services.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.